液基细胞学检查联合SCCA、CA153检测对宫颈癌诊断的应用研究

doi:10.3969/j.issn.1000-8535.2022.05.008

摘要/Abstract

摘要： 目的探究液基细胞学检查联合鳞状上皮细胞癌抗原(SCCA)、癌抗原153(CA153)检测对宫颈癌诊断价值。方法对子宫颈上皮内瘤变患者54例(内瘤变组)、子宫颈癌患者54例(宫颈癌组)及健康体检者54例(对照组)进行液基细胞学、血清SCCA、血清CA153进行检测,以病理活检诊断为金标准。分析液基细胞学检查、血清中SCCA、血清中CA153对宫颈癌诊断价值,并分析联合液基细胞学检查与血清中SCCA、血清中CA153检测的临床价值。结果内瘤变组和宫颈癌组血清SCCA、CA153水平均高于对照组,宫颈癌组血清SCCA、CA153水平高于内瘤变组(P均<0.05)。单项检测中,液基细胞学检查阳性率高于SCCA、CA153,联合检测阳性率与其他各单项检测相比明显提高(P<0.05)。结论宫颈癌患者体内SCCA、CA153水平高,液基细胞学检查联合SCCA、CA153检测对宫颈癌早期阳性检出率高。

关键词: 液基细胞学检查, SCCA, CA153, 宫颈癌

Abstract: Objective To explore the diagnostic value of liquid-based cytology combined with squamous cell carcinoma antigen (SCCA) and cancer antigen 153 (CA153) detection in patients with cervical cancer. Methods Liquid-based cytology, serum SCCA, and serum CA153 were detected on 54 patients with cervical intraepithelial neoplasia (neoplasia group), 54 patients with cervical cancer (cancer group), and 54 healthy subjects (control group). Pathological biopsy diagnosis was used as the gold standard. The diagnostic value of liquid-based cytology, serum SCCA, and serum CA153 in cervical cancer was analyzed, and the clinical value of combining liquid-based cytology with serum SCCA and serum CA153 detection was also analyzed. Results The levels of serum SCCA and CA153 in neoplasia group and cancer group were higher than those in control group, and the serum SCCA and CA153 levels in the cancer group were higher than those in the neoplasia group (P<0.05). In the single detection, the positive rate of liquid-based cytology was higher than that of serum SCCA and CA153, and the positive rate of combined detection was significantly higher than those of the single detection (P<0.05). Conclusions Cervical cancer patients have high levels of serum SCCA and CA153. Liquid-based cytology combined with SCCA and CA153 detection has high positive rate for early cervical cancer.

Key words: liquid-based cytology, squamous cell carcinoma antigen, cancer antigen 153, cervical cancer

梁锐根, 关燕鸣, 胡力. 液基细胞学检查联合SCCA、CA153检测对宫颈癌诊断的应用研究[J]. 广州医药, 2022, 53(5): 43-46.

LIANG Ruigen, GUAN Yanming, HU Li. Study on the application of liquid-based cytology combined with squamous cell carcinoma antigen and cancer antigen 153 detection in the diagnosis of cervical cancer[J]. Guangzhou Medical Journal, 2022, 53(5): 43-46.

参考文献

[1] 吴继超,马晓晴,许一凡,等. IFN-γ在宫颈癌治疗中的研究进展[J]. 湖北医药学院学报,2021,40(4):433-436.
[2] 李建英. 液基薄层细胞学检测在宫颈癌及癌前病变筛查中的应用[J]. 现代肿瘤医学,2021,29(10):1765-1768.
[3] 聂洁. 血清鳞状上皮细胞癌抗原在不同级别宫颈病变中的表达情况[J]. 山西医药杂志,2020,49(5):513-515.
[4] 陈远平,杜仲,袁竟,等. M-CSF、CA153、HPV联合检测在宫颈癌早期筛查中的临床意义[J]. 国际检验医学杂志,2020,41(6):667-670.
[5] 李静,索红燕,孔为民. 《国际妇产科联盟(FIGO)2018癌症报告:宫颈癌新分期及诊治指南》解读[J]. 中国临床医生杂志,2019,47(6):646-649.
[6] 康山. 子宫颈癌的规范化诊断[J]. 中国实用妇科与产科杂志,2021,37(1):37-41.
[7] 张涛,刘宁宁,田睿红. SCCA、miR-501在宫颈癌患者血清中的表达水平及临床意义[J]. 医学临床研究,2021,38(7):1024-1027.
[8] 张茜,吕文艳,朱武,等. SCC、CEA在宫颈癌中的表达及意义[J]. 实用癌症杂志,2020,35(11):1786-1789.
[9] 余晓辉,周阳春. SCCA、TSGF和CA125在宫颈癌患者血清中的表达水平及其与宫颈癌分期的相关性分析[J]. 国际检验医学杂志,2018,39(9):1131-1134.
[10] 张宁梅,杜伟平,杨静玲. 不同病理分期乳腺癌患者血清CA153、CA125表达变化差异分析[J]. 实用癌症杂志,2020,35(11):1762-1764.
[11] 颜申姬,周慧,房笃智,等. CA153和PLGF在胎盘早剥患者血清中的表达及临床意义[J]. 临床输血与检验,2019,21(5):524-526.
[12] 扈成伟,郭九玲,李冬霞,等. 非小细胞肺癌组织中CA199、CA153、CYFRA21-1的表达及其与临床病理特征的相关性[J]. 现代肿瘤医学,2021,29(3):418-422.
[13] 曾贝贝,张步腾,杜贤,等. SCC、CA199、CA153和CEA在老年子宫内膜癌患者中的表达及与生存期的相关性[J]. 西部医学,2021,33(2):262-265,270.
[14] 印海娟,胡金琎,张林光,等. HPV、CA125、CA153、CA199联合检测对宫颈癌的诊断价值[J]. 中国性科学,2019,28(12):37-40.
[15] 薛雯娣,宫美丽,李旭,等. 高级别宫颈上皮内瘤变及宫颈癌患者宫颈液基薄层细胞学检查和高危型人乳头状瘤病毒检测结果分析[J]. 中国药物与临床,2021,21(3):492-494.
[16] 唐慧琳,郭秀娟,应春妹. 鳞状细胞癌相关抗原、CA153、CA199联合检测对宫颈癌诊断及预后判断的临床价值[J]. 中国妇幼保健,2019,34(17):3935-3937.
[17] 阿衣西布卫·库尔班,战英杰,王景,等. 细胞角质蛋白19片段抗原21-1、鳞状细胞癌抗原和糖类抗原153联合检测对宫颈癌的诊断价值[J]. 癌症进展,2020,18(11):1167-1170.
[18] 罗明兰,艾丹,邓春雷. 液基细胞学检查联合血清SCCA水平检测在宫颈癌癌前病变诊断中应用价值研究[J]. 湖南师范大学学报(医学版),2020,17(5):183-186.